John Bell (physician)

Sir John Irving Bell GBE FRS FMedSci FREng[1] (born 1 July 1952)[2] is a Canadian immunologist and geneticist.[3] From 2006 to 2011, he was President of the Academy of Medical Sciences, and since 2002 he has held the Regius Chair of Medicine at the University of Oxford, UK.[4] He has been Chairman of OSCHR since 2006.

Sir John Bell

GBE FRS FMedSci FREng
Born
John Irving Bell

(1952-07-01) 1 July 1952
Edmonton, Alberta, Canada
NationalityCanadian
Alma materUniversity of Alberta
University of Oxford

Education and career

Bell was born in Edmonton, Alberta, where his parents worked in haematology and pharmacy. He attended Ridley College in St. Catharines, Canada. He graduated from the University of Alberta in 1975, and then studied medicine on a Rhodes Scholarship at the University of Oxford.[4] In 1982, he took up a position as Clinical Fellow in Immunology with Hugh McDevitt at Stanford University, California, USA, where he worked on histocompatibility antigens and autoimmune disease.[4][5][6]

In 1987 Bell returned to Oxford as a Wellcome Trust Senior Clinical Fellow, and joined the Institute of Molecular Medicine, founded by David Weatherall. In 1992 he succeeded Weatherall as the Nuffield Professor of Clinical Medicine and, in 2002, became the Regius Professor of Medicine at Oxford, also after Weatherall. In 1994, Bell was one of the founders of the Wellcome Trust Centre for Human Genetics at Oxford University.[4][5] He is an emeritus fellow of Magdalen College, Oxford and a Student of Christ Church, Oxford. He sat on the Council of the Medical Research Council 1998–2003. Since 2011, Bell has been one of two Life Sciences Champions for the UK, reporting to the Prime Minister.

Directorships, consulting and charity positions

Bell has been a non-executive director of Roche since 2001.[7] A BMJ campaign to make the results of unpublished studies on the anti-influenza drug oseltamivir (Tamiflu) available to researchers led to the journal's editor Fiona Godlee urging Bell "as an internationally respected scientist and clinician and a leader of clinical research in the United Kingdom, to bring your influence to bear on your colleagues on Roche's board."[8] Roche subsequently agreed to a wide policy of data transparency in clinical trials. Matthew Thompson and Carl Heneghan wrote in a letter to the journal "...according to Roche's 2011 financial report, John Bell received 390 000 Swiss Francs (£260 450; €322 450; $420 000) last year for his role on the board of directors. What do Roche and its shareholders expect for this level of involvement and remuneration?"[9][10] The House of Commons Science and Technology Committee report on the subject broadly supported the release of more clinical trial data but urged caution on public release of individual patient data.

Bell serves on the Genentech Board in San Francisco, and formerly served on the scientific advisory board of AstraZeneca (1997–2000).[5] He was the founding director of three biotechnology companies,[4][5] including Oxagen, Avidex, and Powderject and is also on the Board of Atopix.

His charity positions include chairing the board of trustees of the Oxford Health Alliance[6] and the science committee of the UK Biobank.[11] He chairs the Global Health Scientific advisory board of the Bill & Melinda Gates Foundation, he is a Trustee of the Rhodes Trust, he sits on the award jury of the Gairdner Foundation, he is a non-executive member of Genomics England, and he is a member of Cancer Research UK. He has advised governments and foundations in Singapore, France, Canada, Sweden, Finland, and Alberta on biomedical research. He is on the Jenner Institute Board and the Gray Institute Board. He is on the advisory Board for the McGill Genomics Institute and the Montreal Neurological Institute, and chairs the advisory board for the Oak Foundation and the Robertson Foundation. He attended the 2013 Bilderberg Group conference.[12]

Research

Bell's research has identified genes involved in susceptibility to diabetes mellitus type 1 and rheumatoid arthritis and multiple sclerosis. His work has been important in elucidating the interactions on the surface of the T cell involved in immune activation. He has also worked on the biomedical applications of high-throughput genomic technologies, including structural genomics and ENU mutagenesis.[5] He has been directly involved in applying genetics in a clinical settings and helped developed the 100,000 genome project in England.

Awards and honours

Bell was elected a Fellow of the Academy of Medical Sciences (FMedSci) in 1998.[13] He was awarded an honorary D.Sc. degree by the University of Alberta in 2003.[14] Bell was President of the Academy of Medical Sciences from 2006 to 2011.[4][15] In 2008, he was elected a Fellow of the Royal Society (FRS).[16] He was appointed an Honorary Fellow of the Royal Academy of Engineering (HonFREng)[1][1] in 2009, [17] and was knighted for services to medicine in the New Year Honours of that year.[18] He has received honorary degrees from the Universities of York, Warwick, Glasgow, Dundee, Imperial College and University of Toronto (2014). He was appointed Knight Grand Cross of the Order of the British Empire (GBE) in the 2015 New Year Honours for services to medicine, medical research and the life science industry.[19][20] In addition to Sir Charles Gordon and Sir Edward Beatty, he is one of the few Canadians to be admitted to the highest class in this order.

gollark: Vazkii has that patchouli thing.
gollark: Also, with so many complex multiblocks, I think actually usable text documentation would be a good feature.
gollark: <@404656680496791554> that's worse.
gollark: Well, that's a shame, I'd have liked more variety there.
gollark: It'll be ridiculously hard to run reactors at any sort of high power if all the fuels get heat scaled up about that much.

References
  1. "List of Fellows".
  2. "Prof Sir John Bell". Debretts-01-03.
  3. Curriculum vitae: John Irving Bell (accessed 21 December 2008)
  4. Watts, G. (2008). "John Bell: A Canadian at the top of UK academic medicine". The Lancet. 372 (9652): 1801–1822. doi:10.1016/S0140-6736(08)61748-1. PMID 19027476.
  5. Professor John Bell, PMedSci – A Biographical Note, 21 December 2008)
  6. The Oxford Health Alliance: Sir John Bell Archived 8 December 2008 at the Wayback Machine (accessed 21 December 2008)
  7. Roche: Board of Directors (accessed 21 December 2008)
  8. Godlee F. Open letter to Roche about oseltamivir trial data. BMJ 345:e7305
  9. Thompson M, Heneghan C. (2012) We need to move the debate on open clinical trial data forward. BMJ 345:e8351
  10. Roche: Finance Report 2011 Archived 3 December 2013 at the Wayback Machine (accessed 24 March 2013)
  11. UK Biobank: Board of Directors Archived 26 December 2008 at the Wayback Machine (accessed 21 December 2008)
  12. Business Insider: The Full List Of Incredibly Powerful People Who Will Attend This Year's Bilderberg Meeting (accessed 28 November 2013)
  13. Ordinary Fellows: Professor Sir John Bell
  14. University of Alberta: Past Honorary Degree Recipients: B Archived 27 May 2011 at the Wayback Machine (accessed 21 December 2008)
  15. Academy President: Professor Sir John Bell (accessed 18 January 2015)
  16. Royal Society: Library and Archive catalogue: Bell; John Irving; Sir (accessed 21 December 2008)
  17. Royal Society: New Fellows – 2008: Agarwal–Cohen (accessed 21 December 2008)
  18. BBC: 29/12/07 honours list (accessed 21 December 2008)
  19. "No. 61092". The London Gazette (Supplement). 31 December 2014. p. N8.
  20. 2015 New Year Honours List Archived 2 January 2015 at the Wayback Machine
Educational offices
Preceded by
Sir Keith Peters		 President of the Academy of Medical Sciences, United Kingdom
2006–2011		 Succeeded by
Sir John Tooke
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.